FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2321839092> ?p ?o ?g. }

• W2321839092 abstract "You have accessJournal of UrologyProstate Cancer: Detection & Screening IV1 Apr 2014MP67-16 INCIDENTAL ABNORMAL FDG UPTAKE IN PROSTATE ON 18-FLUORO-2-DEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY IMAGES Dong Il Kang, Pil Moon Kang, Won Ik Seo, Sang Kyun Bae, Wan Suk Kim, and Jae Min Chung Dong Il KangDong Il Kang More articles by this author , Pil Moon KangPil Moon Kang More articles by this author , Won Ik SeoWon Ik Seo More articles by this author , Sang Kyun BaeSang Kyun Bae More articles by this author , Wan Suk KimWan Suk Kim More articles by this author , and Jae Min ChungJae Min Chung More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.2083AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES 18-fluoro-2-deoxyglucose positron emission tomography-computed tomography (FDG PET/CT) scan is commonly used for staging and restaging of various malignancies such as head and neck, breast, colorectal and gynecological cancer. Several investigators had reported the incidental detection of prostate cancer with abnormal FDG uptake. The aim of this study is to evaluate the clinical value of incidental prostate uptake on FDG PET/CT. METHODS We reviewed PET/CT reports from September 2009 to September 2013 and selected cases with focal/diffuse FDG uptake in prostate. Patients with known prostate cancer or invasive malignancy to prostate were excluded. We analyzed the correlation between PET/CT finding and data of additional evaluation such as serum prostate-specific antigen (PSA) levels, digital rectal examination (DRE), Transrectal ultrasound (TRUS) and/or biopsy to confirm prostate cancer. RESULTS Of a total of 18.393 cases, 106 (0.6%) showed abnormal hypermetabolism in the prostate. Additional evaluation was carried out in 66 patients. Serum PSA level was not statistically correlated with SUVmax in all patients (rho 0.182, p=0.144). Biopsy was performed in 15 patients and prostate cancer was confirmed in 11 patients. The median serum PSA level was 4.8 (0.55∼7.06) ng/mL and 17.0 (1.06∼495) ng/mL in the benign group and prostate cancer group, respectively. The median SUV max was higher in the cancer group (7.4 (4.4∼24.5)) than in the benign groups (4.3(3.1∼8.8)) but the difference was not statically significant (p=0.176). There was no significant correlation between SUVmax and serum PSA, prostatic volume or Gleason score. CONCLUSIONS PET/CT did not reliably differentiate malignant or benign from abnormal uptake lesion in prostate and routine prostate biopsy was usually not recommended in all patients with abnormal FDG uptake. However, patients with incidental uptake in prostate on PET/CT should not be ignored and should be further clinical evaluation such as PSA and DRE. Comparison between benign and malignant groups Benign group (n= 4 ) Malignant group (n=11) Age (median, years) 72 (range 64-81) 71.6 (range 61-87) Serum PSA level (ng/mL), median 4.8 7.4 0-2.9 1 1 3.0-9.9 3 3 10.0-19.9 2 ≥20 5 Biopsy: Gleason score 6 0 7 3 ≥8 8 SUVmax, median(range) 4.3 (range 3.1-8.8) 7.4 (range 4.4-24.5) © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e755-e756 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Dong Il Kang More articles by this author Pil Moon Kang More articles by this author Won Ik Seo More articles by this author Sang Kyun Bae More articles by this author Wan Suk Kim More articles by this author Jae Min Chung More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ..." @default.
• W2321839092 created "2016-06-24" @default.
• W2321839092 creator A5012828419 @default.
• W2321839092 creator A5036104509 @default.
• W2321839092 creator A5037435240 @default.
• W2321839092 creator A5078230144 @default.
• W2321839092 creator A5087987775 @default.
• W2321839092 creator A5091270075 @default.
• W2321839092 date "2014-04-01" @default.
• W2321839092 modified "2023-09-23" @default.
• W2321839092 title "MP67-16 INCIDENTAL ABNORMAL FDG UPTAKE IN PROSTATE ON 18-FLUORO-2-DEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY IMAGES" @default.
• W2321839092 doi "https://doi.org/10.1016/j.juro.2014.02.2083" @default.
• W2321839092 hasPublicationYear "2014" @default.
• W2321839092 type Work @default.
• W2321839092 sameAs 2321839092 @default.
• W2321839092 citedByCount "0" @default.
• W2321839092 crossrefType "journal-article" @default.
• W2321839092 hasAuthorship W2321839092A5012828419 @default.
• W2321839092 hasAuthorship W2321839092A5036104509 @default.
• W2321839092 hasAuthorship W2321839092A5037435240 @default.
• W2321839092 hasAuthorship W2321839092A5078230144 @default.
• W2321839092 hasAuthorship W2321839092A5087987775 @default.
• W2321839092 hasAuthorship W2321839092A5091270075 @default.
• W2321839092 hasConcept C121608353 @default.
• W2321839092 hasConcept C126322002 @default.
• W2321839092 hasConcept C126838900 @default.
• W2321839092 hasConcept C142724271 @default.
• W2321839092 hasConcept C2775842073 @default.
• W2321839092 hasConcept C2776235491 @default.
• W2321839092 hasConcept C2779399171 @default.
• W2321839092 hasConcept C2780192828 @default.
• W2321839092 hasConcept C2908761598 @default.
• W2321839092 hasConcept C2989005 @default.
• W2321839092 hasConcept C37097830 @default.
• W2321839092 hasConcept C71924100 @default.
• W2321839092 hasConceptScore W2321839092C121608353 @default.
• W2321839092 hasConceptScore W2321839092C126322002 @default.
• W2321839092 hasConceptScore W2321839092C126838900 @default.
• W2321839092 hasConceptScore W2321839092C142724271 @default.
• W2321839092 hasConceptScore W2321839092C2775842073 @default.
• W2321839092 hasConceptScore W2321839092C2776235491 @default.
• W2321839092 hasConceptScore W2321839092C2779399171 @default.
• W2321839092 hasConceptScore W2321839092C2780192828 @default.
• W2321839092 hasConceptScore W2321839092C2908761598 @default.
• W2321839092 hasConceptScore W2321839092C2989005 @default.
• W2321839092 hasConceptScore W2321839092C37097830 @default.
• W2321839092 hasConceptScore W2321839092C71924100 @default.
• W2321839092 hasIssue "4S" @default.
• W2321839092 hasLocation W23218390921 @default.
• W2321839092 hasOpenAccess W2321839092 @default.
• W2321839092 hasPrimaryLocation W23218390921 @default.
• W2321839092 hasRelatedWork W1963655545 @default.
• W2321839092 hasRelatedWork W2043615801 @default.
• W2321839092 hasRelatedWork W2056929691 @default.
• W2321839092 hasRelatedWork W2067891291 @default.
• W2321839092 hasRelatedWork W2077398110 @default.
• W2321839092 hasRelatedWork W2165919621 @default.
• W2321839092 hasRelatedWork W2736007806 @default.
• W2321839092 hasRelatedWork W2976224709 @default.
• W2321839092 hasRelatedWork W4360954486 @default.
• W2321839092 hasRelatedWork W2512291173 @default.
• W2321839092 hasVolume "191" @default.
• W2321839092 isParatext "false" @default.
• W2321839092 isRetracted "false" @default.
• W2321839092 magId "2321839092" @default.
• W2321839092 workType "article" @default.